<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36825983</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Estimating glucocorticoid-related morbidity in lupus nephritis using the glucocorticoid toxicity index.</ArticleTitle><Pagination><StartPage>565</StartPage><EndPage>570</EndPage><MedlinePgn>565-570</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231160969</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Lupus nephritis (LN) is often treated with high doses of glucocorticoids (GCs). The glucocorticoid toxicity index (GTI) was developed by expert consensus to quantify GC toxicity. To date, the GTI has not been shown to correlate with GC exposure in patients with LN.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective cohort study of patients with biopsy-confirmed LN between 2006 and 2016. Cumulative GC exposure and GTI scores were determined via medical record review. Both the aggregate improvement score (GTI-AIS) and the cumulative worsening score (GTI-CWS) were calculated. We performed linear regression to determine the association between GC exposure and GTI scores at 1&#xa0;year and 5&#xa0;years following kidney biopsy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This study included 49 patients with a mean age of 33.3 (SD 9.5) years. Mean GC exposure was 23.0&#xa0;mg prednisone-equivalents per day through year 1 and 9.9&#xa0;mg prednisone-equivalents per day through year 5. At 5&#xa0;years, higher GC exposure was associated with higher GTI-AIS (<i>p</i> &lt; 0.001) and GTI-CWS (<i>p</i> = 0.002), and this association persisted in multivariate analysis adjusting for age, sex, race, induction medication, and nephritis class (<i>p</i> = 0.026 for AIS, <i>p</i> = 0.012 for CWS). At 1&#xa0;year, GC exposure was not associated with GTI scores (<i>p</i> = 0.70 for AIS; <i>p</i> = 0.58 for CWS).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this cohort study, the GTI was associated with cumulative steroid exposure at 5&#xa0;years after diagnosis. In patients with LN, the GTI may serve as a useful outcome measure in future LN trials evaluating the steroid sparing effect of novel therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Usiskin</LastName><ForeName>Ilana M</ForeName><Initials>IM</Initials><Identifier Source="ORCID">0000-0001-5527-2597</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States.</Affiliation><Identifier Source="RINGGOLD">1859</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kyttaris</LastName><ForeName>Vasileios C</ForeName><Initials>VC</Initials><Identifier Source="ORCID">0000-0001-7652-3826</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, United States.</Affiliation><Identifier Source="RINGGOLD">1859</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Nephritis</Keyword><Keyword MajorTopicYN="N">renal lupus</Keyword><Keyword MajorTopicYN="N">systematic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>24</Day><Hour>9</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36825983</ArticleId><ArticleId IdType="doi">10.1177/09612033231160969</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>